Skip to content

Briganti nomogram calculator: risk of lymph node involvement

The risk of lymph node cancer from the 2019 nomogram, the 7% cut-off and what it changes in surgery.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 20, 2026
Book a consultation
Drawing of a prostate MRI image with a purple lesion, linked by a lymphatic vessel to a chain of lymph nodes, one of them highlighted, and a half-moon dial with the needle near the start of the scale
On this page

Quick answer

The Briganti nomogram estimates, before radical prostatectomy, the chance that the cancer has reached the pelvic lymph nodes. The 2019 version uses the PSA, the MRI and the results of the targeted and systematic biopsies, and the study that developed it proposed a 7% cut-off.4 Below it, lymph node dissection can be spared. In my practice, I use the 2019 nomogram with that cut-off and follow the European guideline, which does not set a number.1 The result is an estimate to bring to your consultation.

Calculate your risk with the 2019 nomogram

You will need your latest PSA, the MRI report and the biopsy report, with the results of the targeted biopsy (from the MRI target) separate from those of the systematic biopsy. If the report does not separate them, ask the urologist who did the biopsy.

Your answers stay in your browser. Nothing is sent, stored or saved in cookies, and everything is cleared when you close the page.

This calculation is for men who had an MRI-targeted biopsy showing cancer together with a systematic biopsy (cores taken from the rest of the prostate).

Your most recent blood test result. Example: 7.5
What the MRI shows at the edge of the prostateIt is in the MRI report. If the report mentions both, choose the seminal vesicles.
The largest diameter of the lesion with the highest PI-RADS score. If two have the same score, use the larger one. Example: 14
ISUP grade group on the targeted biopsy (from the MRI target)If there is more than one target, use the highest grade.
Only those from the rest of the prostate, not the target cores. Example: 12
Cores with Gleason 3+4 or higher. If none, enter 0.

Result

Fill in the fields, then tap Calculate the risk.

The calculation is the logistic regression published in the 2019 study, using the coefficients from the supplementary table of the original article.4,5 If you had a conventional biopsy without MRI, this calculation does not apply. The page on fusion biopsy explains the difference.

The information in the calculation

  • PSA: your blood test result before surgery, in ng/mL. Each extra point raises the risk slightly.4
  • What the MRI shows at the edge of the prostate: tumour inside the prostate, extracapsular extension (the tumour goes through the capsule) or seminal vesicle invasion. These categories exclude each other: if the report mentions the last two, the seminal vesicles count.4 The page on MRI and PI-RADS explains the report.
  • Size of the main lesion: the largest diameter, in millimetres, of the lesion with the highest PI-RADS score. If two lesions have the same score, the larger one counts.4
  • ISUP grade group on the targeted biopsy: ISUP 1 or 2, ISUP 3, or ISUP 4 or 5, in the target core.4 The page on Gleason and ISUP explains the grades.
  • Systematic cores with significant cancer: the percentage of cores taken from the rest of the prostate, outside the target, that had ISUP 2 or higher cancer.4 Cores with ISUP 1 only do not count.

For anyone who wants to check the calculation, these are the numbers of the model:4,5

ItemCoefficientOdds ratio
Intercept−4.5974not applicable
PSA (per ng/mL)0.04161.04
Extracapsular extension on MRI1.22143.39
Seminal vesicle invasion on MRI1.46724.36
Lesion size (per mm)0.03111.03
ISUP 3 on targeted biopsy1.20323.33
ISUP 4 or 5 on targeted biopsy1.80636.08
% of systematic cores with ISUP 2 or higher (per point)0.01191.01

Adding up the coefficients gives a value called the linear predictor, and the risk is 1 divided by (1 + e to the power of minus that value). The right-hand column shows the odds ratios published in the 2019 article. For seminal vesicle invasion, the coefficient from the supplementary table gives 4.34, slightly below the 4.36 printed in the article, a difference that probably comes from rounding.4,5

The 7% cut-off

The 2019 study included 497 patients from 5 European centres, all treated with extended lymph node dissection, and 12.5% of them had cancer in the lymph nodes.4 With the 7% cut-off, 244 dissections (57%) would be avoided, and only 4 of those patients had a node with cancer. The new model missed fewer cases than the 2012 and 2017 Briganti nomograms and the Memorial Sloan Kettering nomogram, applied to the same patients.4

The 2026 European guideline does not set a number. It explains that every cut-off trades the risk of leaving a node with cancer against the extra operating time and the complications of the dissection.1 When the lymph nodes are removed, the guideline recommends an extended dissection.2 The page on pelvic lymph node dissection explains the surgery, the complications and what the randomised trials show.

What about the 2012 nomogram?

The 2012 Briganti nomogram was built for conventional biopsy, guided by ultrasound only. It uses the PSA, the clinical stage on rectal exam, the primary and secondary Gleason grades on biopsy and the percentage of cores with cancer.3 It was developed in 588 patients from a single centre, 8.3% of whom had cancer in the lymph nodes. With the 5% cut-off, 65.5% would avoid the dissection, and 6 node-positive patients would go without it.3

It is not in this calculator because its coefficients are not available in an open source for checking. The original article is in the references. In men who had an MRI-targeted biopsy, the 2019 study itself showed that models built on conventional biopsy are less accurate.4

What the nomogram does not show

The nomogram was developed in patients treated at 5 European centres, and its accuracy drops when it is used elsewhere. In a validation of 481 patients at 3 French centres, published in 2026, its ability to separate men with and without lymph node cancer varied a lot between centres, and the model overestimated the risk in centres with fewer node-positive cases.5 The authors concluded that the most suitable cut-off differs from one centre to another.

The model also does not include the PSMA PET. The PET is more sensitive than MRI and CT for lymph nodes, but it cannot see deposits smaller than about 5 mm.1 And the nomogram knows nothing about your health, your age or what you want to preserve. That is why the result is something to discuss at your consultation.

My approach

Before prostatectomy, I work out the chance that the cancer has reached the lymph nodes. I use the Briganti nomograms, the 2019 version with the 7% cut-off for men who had an MRI-guided biopsy, and I follow the European guideline. The PSMA PET, when indicated, is part of the same discussion.

When lymph node removal is indicated, it is always an extended dissection, done robotically during the same robotic radical prostatectomy. After surgery, I go through the prostatectomy pathology report with you, including how many nodes were examined and how many had cancer. If you would like another opinion on the plan, a second opinion can be done entirely online, in English, with your tests sent in advance. The site's other tools are on the calculators page.

Send your case

If you have been advised to have a prostatectomy and would like my opinion on your case, including the lymph nodes, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is the Briganti nomogram?

It is a calculation that estimates, before radical prostatectomy, the chance that prostate cancer has reached the pelvic lymph nodes. It was developed by Alberto Briganti's team in Milan and has more than one version. The 2012 version was built for conventional biopsy, and the 2019 version for men who had an MRI-targeted biopsy together with a systematic biopsy.3,4 The result helps decide whether the lymph nodes should be removed during surgery.

What is the cut-off for the 2019 Briganti nomogram?

The 2019 study proposed a 7% cut-off. With it, 57% of lymph node dissections would be avoided, and among the 244 patients who would not have the dissection, 4 had cancer in the lymph nodes.4 For the 2012 version, the proposed cut-off was 5%.3 The European guideline does not set a number and points out that every cut-off is a trade-off between missing a node with cancer and adding time and complications to the operation.1 I use the 7% cut-off with the 2019 nomogram.

Can I use this calculator if I had a conventional biopsy without MRI?

No. The 2019 nomogram applies only to men who had cancer on an MRI-targeted biopsy and a systematic biopsy in the same procedure.4 For conventional biopsy there is the 2012 version, which uses the PSA, the clinical stage, the Gleason grades and the percentage of cores with cancer.3 It is not included in this calculator.

If my result is below 7%, does that mean I have no cancer in the lymph nodes?

It means the estimated risk is low, but not zero. In the original study, 4 of the 244 patients below the cut-off had cancer in the lymph nodes.4 In a validation at 3 French centres, the proportion of node-positive cases below 7% ranged from 0% to 8.9%, depending on the centre.5

Does a PSMA PET replace the nomogram?

Not yet. A PSMA PET is more sensitive than MRI and CT for lymph nodes, but it cannot see deposits smaller than about 5 mm. That is why the European guideline still uses nomograms, and the PET result is part of the same discussion.1

My MRI showed extension outside the capsule. Does that change the result much?

It does. In the 2019 model, extracapsular extension on MRI multiplied the odds of lymph node cancer by about 3.4, and seminal vesicle invasion by about 4.4, compared with a tumour inside the prostate. ISUP 4 or 5 on the targeted biopsy multiplied them by about 6.4

Who decides on lymph node removal during prostatectomy in São Paulo?

I perform robotic radical prostatectomy in São Paulo and decide on lymph node removal using the Briganti nomograms. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275, and a reference in prostate cancer. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. When I remove the lymph nodes, I always do an extended dissection. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: diagnostic evaluation. European Association of Urology; 2026. EAU
  2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  3. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61(3):480-487. PubMed
  4. Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2019;75(3):506-514. PubMed
  5. Peyrottes A, Orlhac F, Colau A, et al. Multicentre Validation of the 2019 Briganti Nomogram: One Threshold Does Not Fit All. Int Braz J Urol. 2026;52(4):e20260023. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides